- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
Patent holdings for IPC class A61K 31/439
Total number of patents in this class: 2266
10-year publication summary
|
203
|
180
|
191
|
201
|
209
|
178
|
186
|
164
|
125
|
65
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Wockhardt Limited | 227 |
50 |
| Genzyme Corporation | 1233 |
38 |
| Novartis AG | 10904 |
36 |
| Lenz Therapeutics Operations, Inc. | 38 |
32 |
| Chiesi Farmaceutici S.p.A. | 952 |
31 |
| AstraZeneca AB | 2928 |
29 |
| Bristol-myers Squibb Company | 4892 |
26 |
| Merck Sharp & Dohme LLC | 3741 |
26 |
| Meiji Seika Pharma Co., Ltd. | 248 |
24 |
| Boehringer Ingelheim International GmbH | 4704 |
21 |
| Vertex Pharmaceuticals Incorporated | 1596 |
19 |
| Centre National de La Recherche Scientifique | 10321 |
18 |
| Theravance Biopharma R&D IP, LLC | 462 |
17 |
| Astellas Pharma Inc. | 1086 |
16 |
| The Scripps Research Institute | 1346 |
15 |
| Glaxo Group Limited | 4132 |
14 |
| Pfizer Inc. | 3367 |
14 |
| Gilead Sciences, Inc. | 2028 |
13 |
| Alkermes Pharma Ireland Limited | 271 |
12 |
| Mutabilis | 27 |
12 |
| Other owners | 1803 |